NCT00448201 · MORE INFO

Limitations, agreements, and source contact

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease · Source last updated 2017-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: true

limitations And Caveats

description: Per the protocol, non-serious adverse events were not captured as this was a high-dose transplant study and grades 1,2, and 3 adverse events were expected. No unexpected toxicities were seen beyond those reported in the Serious Adverse Event section.

point Of Contact

email: tom_shea@med.unc.edu
organization: UNC Lineberger Comprehensive Cancer Center
phone: 919-966-7746
title: Dr. Thomas Shea

Complete source fields

certain Agreement

pi Sponsor Employee: true

limitations And Caveats

description: Per the protocol, non-serious adverse events were not captured as this was a high-dose transplant study and grades 1,2, and 3 adverse events were expected. No unexpected toxicities were seen beyond those reported in the Serious Adverse Event section.

point Of Contact

email: tom_shea@med.unc.edu
organization: UNC Lineberger Comprehensive Cancer Center
phone: 919-966-7746
title: Dr. Thomas Shea

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice